14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $0.87 $1.65 Wednesday, 24th Apr 2024 ADAP stock ended at $1.08. This is 5.26% less than the trading day before Tuesday, 23rd Apr 2024. During the day the stock fluctuated 7.48% from a day low at $1.07 to a day high of $1.15.
90 days $0.691 $2.05
52 weeks $0.420 $2.05

Historical Adaptimmune Therapeutics plc prices

Date Open High Low Close Volume
Nov 29, 2023 $0.446 $0.508 $0.440 $0.498 285 707
Nov 28, 2023 $0.469 $0.480 $0.421 $0.446 362 270
Nov 27, 2023 $0.470 $0.480 $0.447 $0.475 425 760
Nov 24, 2023 $0.449 $0.470 $0.433 $0.465 367 051
Nov 22, 2023 $0.437 $0.460 $0.430 $0.449 280 773
Nov 21, 2023 $0.447 $0.450 $0.420 $0.442 413 151
Nov 20, 2023 $0.500 $0.500 $0.420 $0.429 1 156 445
Nov 17, 2023 $0.515 $0.520 $0.441 $0.479 1 050 164
Nov 16, 2023 $0.517 $0.530 $0.491 $0.500 233 522
Nov 15, 2023 $0.490 $0.530 $0.490 $0.500 444 327
Nov 14, 2023 $0.502 $0.530 $0.480 $0.494 350 400
Nov 13, 2023 $0.480 $0.500 $0.450 $0.473 307 494
Nov 10, 2023 $0.540 $0.540 $0.470 $0.470 622 171
Nov 09, 2023 $0.551 $0.571 $0.510 $0.547 422 328
Nov 08, 2023 $0.570 $0.600 $0.550 $0.563 238 500
Nov 07, 2023 $0.596 $0.600 $0.550 $0.596 215 447
Nov 06, 2023 $0.580 $0.596 $0.550 $0.587 130 628
Nov 03, 2023 $0.550 $0.584 $0.540 $0.560 313 024
Nov 02, 2023 $0.538 $0.560 $0.520 $0.554 354 870
Nov 01, 2023 $0.550 $0.565 $0.528 $0.540 382 807
Oct 31, 2023 $0.570 $0.570 $0.530 $0.541 282 523
Oct 30, 2023 $0.580 $0.590 $0.540 $0.555 197 565
Oct 27, 2023 $0.569 $0.580 $0.550 $0.550 227 989
Oct 26, 2023 $0.596 $0.599 $0.555 $0.560 559 638
Oct 25, 2023 $0.620 $0.620 $0.570 $0.595 322 348
Click to get the best stock tips daily for free!

About Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposa... ADAP Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT